Literature DB >> 18677673

General effect on high-risk persons when general practitioners are trained in intensive treatment of type 2 diabetes.

Signe S Rasmussen1, Charlotte Glümer, Annelli Sandbaek, Torsten Lauritzen, Knut Borch-Johnsen.   

Abstract

OBJECTIVE: Within the frame of a randomized clinical trial to examine whether training of general practitioners (the intervention group) in intensive lifestyle modification and pharmacological treatment of patients with type 2 diabetes has a spillover effect on individuals with impaired fasting glycaemia (IFG) or impaired glucose tolerance (IGT).
DESIGN: A high-risk screening study for type 2 diabetes with an intervention programme, where general practices were randomized to provide standard treatment versus intensive lifestyle modification and pharmacological treatment to newly diagnosed diabetic patients.
SETTING: General practices in Denmark.
SUBJECTS: Of 1821 individuals identified with IFG or IGT, results from oral glucose tolerance tests after one and three years were available in 1510 individuals. MAIN OUTCOME MEASURES: Progression rates from IFG and IGT to diabetes and effect of intervention were estimated in a regression model using interval censoring.
RESULTS: A total of 442 persons developed diabetes. There was no significant overall effect of intervention on progression rates. For risk factors, no difference in rate of change was found between randomization groups, but a difference was found between general practices within the same randomization groups.
CONCLUSION: General practitioners identify a high number of incident diabetes cases in individuals with IFG or IGT found by high-risk screening. Intervention at the general practitioner's level in intensive treatment type 2 diabetes does not have a significant spillover effect reducing the risk of diabetes from pre-diabetic conditions. This could indicate that intervention strategies should be specifically targeted at individuals with IFG or IGT, either by training general practitioners or directly at the individual level.

Entities:  

Mesh:

Year:  2008        PMID: 18677673      PMCID: PMC3409605          DOI: 10.1080/02813430802264624

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  23 in total

1.  Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms.

Authors:  J O Christensen; A Sandbaek; T Lauritzen; K Borch-Johnsen
Journal:  Diabetologia       Date:  2004-09-08       Impact factor: 10.122

2.  Population-based incidence of type 2 diabetes in northern Spain: the Asturias Study.

Authors:  Sergio Valdés; Patricia Botas; Elias Delgado; Francisco Alvarez; Francisco Diaz Cadórniga
Journal:  Diabetes Care       Date:  2007-05-29       Impact factor: 19.112

3.  Interval censored survival data: a generalized linear modelling approach.

Authors:  C P Farrington
Journal:  Stat Med       Date:  1996-02-15       Impact factor: 2.373

4.  Regression models for interval censored survival data: application to HIV infection in Danish homosexual men.

Authors:  B Carstensen
Journal:  Stat Med       Date:  1996-10-30       Impact factor: 2.373

5.  A randomized trial of continuing medical education.

Authors:  J C Sibley; D L Sackett; V Neufeld; B Gerrard; K V Rudnick; W Fraser
Journal:  N Engl J Med       Date:  1982-03-04       Impact factor: 91.245

6.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

7.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Authors:  J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

8.  Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.

Authors:  Kinori Kosaka; Mitsuihiko Noda; Takeshi Kuzuya
Journal:  Diabetes Res Clin Pract       Date:  2005-02       Impact factor: 5.602

9.  General health screenings to improve cardiovascular risk profiles: a randomized controlled trial in general practice with 5-year follow-up.

Authors:  Marianne Engberg; Bo Christensen; Bo Karlsmose; Jorgen Lous; Torsten Lauritzen
Journal:  J Fam Pract       Date:  2002-06       Impact factor: 0.493

10.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

View more
  3 in total

1.  The effect of screening on the prevalence of diagnosed type 2 diabetes in primary care.

Authors:  Mark Spigt; Annelies Rikkers; Mirte Doornbos; Evelyn Wouters; Isi Spitz; Ludovic Van Amelsvoort; Paul Zwietering
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

2.  Does training of general practitioners for intensive treatment of people with screen-detected diabetes have a spillover effect on mortality and cardiovascular morbidity in 'at risk' individuals with normoglycaemia? Results from the ADDITION-Denmark cluster-randomised controlled trial.

Authors:  Rebecca K Simmons; Niels H Bruun; Daniel R Witte; Knut Borch-Johnsen; Marit E Jørgensen; Annelli Sandbæk; Torsten Lauritzen
Journal:  Diabetologia       Date:  2017-03-09       Impact factor: 10.122

3.  Does Training and Support of General Practitioners in Intensive Treatment of People with Screen-Detected Diabetes Improve Medication, Morbidity and Mortality in People with Clinically-Diagnosed Diabetes? Investigation of a Spill-Over Effect in a Cluster RCT.

Authors:  Morten Charles; Mette V Skriver; Simon J Griffin; Rebecca K Simmons; Daniel R Witte; Else-Marie Dalsgaard; Torsten Lauritzen; Annelli Sandbæk
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.